Related references
Note: Only part of the references are listed.Pioneer of prostate cancer: past, present and the future ofFOXA1
Mona Teng et al.
PROTEIN & CELL (2021)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
The androgen receptor/filamin A complex as a target in prostate cancer microenvironment
Marzia Di Donato et al.
CELL DEATH & DISEASE (2021)
Clinical and Biological Features of Neuroendocrine Prostate Cancer
Yasutaka Yamada et al.
CURRENT ONCOLOGY REPORTS (2021)
Resistance to Antiandrogens in Prostate Cancer: Is It Inevitable, Intrinsic or Induced?
Norman J. Maitland
CANCERS (2021)
Neuroendocrine prostate cancer has distinctive, non-prostatic HOX code that is represented by the loss of HOXB13 expression
Siyuan Cheng et al.
SCIENTIFIC REPORTS (2021)
Androgen downregulation of miR-760 promotes prostate cancer cell growth by regulating IL6
Shuo Wang et al.
ASIAN JOURNAL OF ANDROLOGY (2021)
The epigenetic and transcriptional landscape of neuroendocrine prostate cancer
Alastair Davies et al.
ENDOCRINE-RELATED CANCER (2020)
Gene Expression Signature Predictive of Neuroendocrine Transformation in Prostate Adenocarcinoma
Paola Ostano et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Maternal Embryonic Leucine Zipper Kinase Promotes Tumor Growth and Metastasis via Stimulating FOXM1 Signaling in Esophageal Squamous Cell Carcinoma
Liang Chen et al.
FRONTIERS IN ONCOLOGY (2020)
Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation
Zeda Zhang et al.
CANCER CELL (2020)
Plasma cell-free DNA-based predictors of response to abiraterone acetate/prednisone and prognostic factors in metastatic castration-resistant prostate cancer
Meijun Du et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2020)
Apalutamide in combination with autophagy inhibitors improves treatment effects in prostate cancer cells
Daniel Eberli et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2020)
Senolytic compounds control a distinct fate of androgen receptor agonist- and antagonist-induced cellular senescent LNCaP prostate cancer cells
Thanakorn Pungsrinont et al.
CELL AND BIOSCIENCE (2020)
The role of microRNA in cisplatin resistance or sensitivity
Shanshan Wang et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2020)
The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling
Boris Y. Shorning et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Mechanisms of Androgen Receptor Agonist- and Antagonist-Mediated Cellular Senescence in Prostate Cancer
Miriam Kokal et al.
CANCERS (2020)
Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer
Yukiyoshi Hirayama et al.
MOLECULAR ONCOLOGY (2020)
Androgen receptor-induced integrin alpha 6 beta 1 and Bnip3 promote survival and resistance to PI3K inhibitors in castration-resistant prostate cancer
Eric A. Nollet et al.
ONCOGENE (2020)
The Androgen Receptor in Prostate Cancer: Effect of Structure, Ligands and Spliced Variants on Therapy
Elisabeth A. Messner et al.
BIOMEDICINES (2020)
Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease
Rebecca Smith et al.
SCIENTIFIC REPORTS (2020)
ACK1-AR and AR-HOXB13 signaling axes: epigenetic regulation of lethal prostate cancers
Eric H. Kim et al.
NAR CANCER (2020)
Androgen receptor co-regulation in prostate cancer
Dhirodatta Senapati et al.
ASIAN JOURNAL OF UROLOGY (2020)
Therapeutic targeting of the androgen receptor (AR) and AR variants in prostate cancer
Ramesh Narayanan
ASIAN JOURNAL OF UROLOGY (2020)
Interference with the androgen receptor protein stability in therapy-resistant prostate cancer
Gopinath Lakshmana et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations
E. David Crawford et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2019)
ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer
Laura Cato et al.
CANCER CELL (2019)
CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis
Michael A. Augello et al.
CANCER CELL (2019)
Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study
Andrew J. Armstrong et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
Karim Fizazi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Reduced T-cell Numbers and Elevated Levels of Immunomodulatory Cytokines in Metastatic Prostate Cancer Patients De Novo Resistant to Abiraterone and/or Enzalutamide Therapy
Sumanta K. Pal et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Inhibition of EGFR signaling with Spautin-1 represents a novel therapeutics for prostate cancer
Yuning Liao et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
HOXB13 EXPRESSION AND ITS ROLE IN PROSTATE CANCER PROGRESSION AND NEUROENDOCRINE DIFFERENTIATION
Farzana Faisal et al.
JOURNAL OF UROLOGY (2019)
Nutlin3a-Loaded Nanoparticles Show Enhanced Apoptotic Activity on Prostate Cancer Cells
Bilge Debelec-Butuner et al.
MOLECULAR BIOTECHNOLOGY (2019)
Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer
Abhijit Parolia et al.
NATURE (2019)
Glucocorticoid receptor upregulation increases radioresistance and triggers androgen independence of prostate cancer
Xiaodong Chen et al.
PROSTATE (2019)
The independent prognostic impact of the GATA2 pioneering factor is restricted to ERG-negative prostate cancer
Franziska Büscheck et al.
TUMOR BIOLOGY (2019)
The Homeobox gene, HOXB13, Regulates a Mitotic Protein-Kinase Interaction Network in Metastatic Prostate Cancers
Jiqiang Yao et al.
SCIENTIFIC REPORTS (2019)
Nerve Growth Factor Induces Proliferation and Aggressiveness in Prostate Cancer Cells
Marzia Di Donato et al.
CANCERS (2019)
p66Shc protein through a redox mechanism enhances the progression of prostate cancer cells towards castration-resistance
Dannah R. Miller et al.
FREE RADICAL BIOLOGY AND MEDICINE (2019)
Non-nuclear AR Signaling in Prostate Cancer
Alice Zamagni et al.
FRONTIERS IN CHEMISTRY (2019)
CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer
Justin H. Hwang et al.
CELL REPORTS (2019)
Polycomb group proteins EZH2 and EED directly regulate androgen receptor in advanced prostate cancer
Qipeng Liu et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
PCAT-1: A Novel Oncogenic Long Non-Coding RNA in Human Cancers
Tiefu Xiong et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2019)
Revealing Metabolic Liabilities of Ralaniten To Enhance Novel Androgen Receptor Targeted Therapies
Jon K. Obst et al.
ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2019)
A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate Cancer
David Y. Takeda et al.
CELL (2018)
p66Shc regulates migration of castration-resistant prostate cancer cells
Matthew A. Ingersoll et al.
CELLULAR SIGNALLING (2018)
Inhibiting autophagy overcomes docetaxel resistance in castration-resistant prostate cancer cells
Quan Wang et al.
INTERNATIONAL UROLOGY AND NEPHROLOGY (2018)
Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study
Rahul Aggarwal et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens
E. David Crawford et al.
JOURNAL OF UROLOGY (2018)
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
Maha Hussain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
HoxB13 mediates AR-V7 activity in prostate cancer
Hector I. Navarro et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13
Zhong Chen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
ADT with antiandrogens in prostate cancer induces adverse effect of increasing resistance, neuroendocrine differentiation and tumor metastasis
Yuanjie Niu et al.
CANCER LETTERS (2018)
The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models
Florian Handle et al.
MOLECULAR CANCER THERAPEUTICS (2018)
ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis
Mirja Rotinen et al.
NATURE MEDICINE (2018)
The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy
Martin Puhr et al.
CLINICAL CANCER RESEARCH (2018)
Cross-talk between androgen receptor and nerve growth factor receptor in prostate cancer cells: implications for a new therapeutic approach
Marzia Di Donato et al.
CELL DEATH DISCOVERY (2018)
Dual androgen receptor (AR) and STAT3 inhibition by a compound targeting the AR amino-terminal domain
Yaping Hua et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2018)
HER2 and EGFR Overexpression Support Metastatic Progression of Prostate Cancer to Bone
Kathleen C. Day et al.
CANCER RESEARCH (2017)
Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer
Santosh Gupta et al.
CLINICAL CANCER RESEARCH (2017)
Src promotes castration-recurrent prostate cancer through androgen receptor-dependent canonical and non-canonical transcriptional signatures
Indranil Chattopadhyay et al.
ONCOTARGET (2017)
The role of p53 in cancer drug resistance and targeted chemotherapy
Karin Hientz et al.
ONCOTARGET (2017)
A Molecular Modeling Study of the Hydroxyflutamide Resistance Mechanism Induced by Androgen Receptor Mutations
Hong-Li Liu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Metformin reverses prostate cancer resistance to enzalutamide by targeting TGF-β1/STAT3 axis-regulated EMT
Qiuli Liu et al.
CELL DEATH & DISEASE (2017)
Epithelial-mesenchymal transition in prostate cancer: an overview
Micaela Montanari et al.
ONCOTARGET (2017)
Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer
Neel Shah et al.
ELIFE (2017)
Neuroendocrine differentiation in prostate cancer: key epigenetic players
Karishma Gupta et al.
TRANSLATIONAL CANCER RESEARCH (2017)
Non-Genomic Actions of the Androgen Receptor in Prostate Cancer
Jacky K. Leung et al.
FRONTIERS IN ENDOCRINOLOGY (2017)
Comparing the rules of engagement of androgen and glucocorticoid receptors
Frank Claessens et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2017)
EPI-001, A Compound Active against Castration-Resistant Prostate Cancer, Targets Transactivation Unit 5 of the Androgen Receptor
Eva De Mol et al.
ACS CHEMICAL BIOLOGY (2016)
N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer
Etienne Dardenne et al.
CANCER CELL (2016)
N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells
John K. Lee et al.
CANCER CELL (2016)
Resistance to Anti-VEGF Therapy Mediated by Autocrine IL6/STAT3 Signaling and Overcome by IL6 Blockade
Alexandra Eichten et al.
CANCER RESEARCH (2016)
Molecular mechanism of R-bicalutamide switching from androgen receptor antagonist to agonist induced by amino acid mutations using molecular dynamics simulations and free energy calculation
Hongli Liu et al.
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN (2016)
Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer
Christine Henzler et al.
NATURE COMMUNICATIONS (2016)
MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner
Felix Y. Feng et al.
NEOPLASIA (2016)
Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer
Sankar N. Maity et al.
SCIENTIFIC REPORTS (2016)
A Targetable GATA2-IGF2 Axis Confers Aggressiveness in Lethal Prostate Cancer
Samuel J. Vidal et al.
CANCER CELL (2015)
Interleukin-6 as a Therapeutic Target
Jean-Francois Rossi et al.
CLINICAL CANCER RESEARCH (2015)
Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models
Paul Toren et al.
EUROPEAN UROLOGY (2015)
Cell death by autophagy: emerging molecular mechanisms and implications for cancer therapy
S. Fulda et al.
ONCOGENE (2015)
Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study
Michael T. Schweizer et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Androgen receptor non-nuclear regulation of prostate cancer cell invasion mediated by Src and matriptase
Jelani C. Zarif et al.
ONCOTARGET (2015)
EGFR mediates docetaxel resistance in human castration-resistant prostate cancer through the Akt-dependent expression of ABCB1 (MDR1)
Tzyh-Chyuan Hour et al.
ARCHIVES OF TOXICOLOGY (2015)
Loss of Androgen Receptor Expression Promotes a Stem-like Cell Phenotype in Prostate Cancer through STAT3 Signaling
Anne Schroeder et al.
CANCER RESEARCH (2014)
PCAT-1, a Long Noncoding RNA, Regulates BRCA2 and Controls Homologous Recombination in Cancer
John R. Prensner et al.
CANCER RESEARCH (2014)
Niclosamide Inhibits Androgen Receptor Variants Expression and Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer
Chengfei Liu et al.
CLINICAL CANCER RESEARCH (2014)
Androgen Receptor Activation in Castration-Recurrent Prostate Cancer: The Role of Src-Family and Ack1 Tyrosine Kinases
Irwin H. Gelman
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2014)
Supraphysiological androgen levels induce cellular senescence in human prostate cancer cells through the Src-Akt pathway
Julia Roediger et al.
MOLECULAR CANCER (2014)
A Natural Androgen Receptor Antagonist Induces Cellular Senescence in Prostate Cancer Cells
Wiebke Hessenkemper et al.
MOLECULAR ENDOCRINOLOGY (2014)
MicroRNAs and Drug Resistance in Prostate Cancers
Feng Li et al.
MOLECULAR PHARMACEUTICS (2014)
Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model
H. G. Nguyen et al.
ONCOGENE (2014)
Molecular pathways and targets in prostate cancer
Emma Shtivelman et al.
ONCOTARGET (2014)
Abiraterone in the treatment of metastatic castration-resistant prostate cancer
Elahe A. Mostaghel
CANCER MANAGEMENT AND RESEARCH (2014)
The Multifaceted Roles of STAT3 Signaling in the Progression of Prostate Cancer
Jennifer L. Bishop et al.
CANCERS (2014)
Src: marker or actor in prostate cancer aggressiveness
Virginie Vlaeminck-Guillem et al.
FRONTIERS IN ONCOLOGY (2014)
Does androgen-ablation therapy (AAT) associated autophagy have a pro-survival effect in LNCaP human prostate cancer cells?
Haley L. Bennett et al.
BJU INTERNATIONAL (2013)
miR-205 negatively regulates the androgen receptor and is associated with adverse outcome of prostate cancer patients
Z. Hagman et al.
BRITISH JOURNAL OF CANCER (2013)
Epigenetic Repression of miR-31 Disrupts Androgen Receptor Homeostasis and Contributes to Prostate Cancer Progression
Pei-Chun Lin et al.
CANCER RESEARCH (2013)
FoxA1 Specifies Unique Androgen and Glucocorticoid Receptor Binding Events in Prostate Cancer Cells
Biswajyoti Sahu et al.
CANCER RESEARCH (2013)
Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade
Vivek K. Arora et al.
CELL (2013)
A Gain-of-Function Mutation in DHT Synthesis in Castration-Resistant Prostate Cancer
Kai-Hsiung Chang et al.
CELL (2013)
Synergistic Targeting of PI3K/AKT Pathway and Androgen Receptor Axis Significantly Delays Castration-Resistant Prostate Cancer Progression In Vivo
Christian Thomas et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial
John C. Araujo et al.
LANCET ONCOLOGY (2013)
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Charles J. Ryan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Androgen deprivation promotes intratumoral synthesis of dihydrotestosterone from androgen metabolites in prostate cancer
Fumio Ishizaki et al.
SCIENTIFIC REPORTS (2013)
Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer
K. Fizazi et al.
EUROPEAN JOURNAL OF CANCER (2012)
The diversity of sex steroid action: novel functions of hydroxysteroid (17β) dehydrogenases as revealed by genetically modified mouse models
Taija Saloniemi et al.
JOURNAL OF ENDOCRINOLOGY (2012)
Cell Autonomous Role of PTEN in Regulating Castration-Resistant Prostate Cancer Growth
David J. Mulholland et al.
CANCER CELL (2011)
Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
Brett S. Carver et al.
CANCER CELL (2011)
Molecular Alterations during Progression of Prostate Cancer to Androgen Independence
Punit Saraon et al.
CLINICAL CHEMISTRY (2011)
Ligand-dependent Corepressor Acts as a Novel Androgen Receptor Corepressor, Inhibits Prostate Cancer Growth, and Is Functionally Inactivated by the Src Protein Kinase
Mohammad Asim et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer
Kai-Hsiung Chang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
The Anti-Interleukin-6 Antibody Siltuximab Down-Regulates Genes Implicated inTumorigenesis in Prostate Cancer Patients From a Phase I Study
Jayaprakash Karkera et al.
PROSTATE (2011)
Clinical and Correlative Results of SWOG S0354: A Phase II Trial of CNTO328 (Siltuximab), a Monoclonal Antibody against Interleukin-6, in Chemotherapy-Pretreated Patients with Castration-Resistant Prostate Cancer
Tanya B. Dorff et al.
CLINICAL CANCER RESEARCH (2010)
The basics of epithelial-mesenchytnal transition (vol 119, pg 1420, 2009)
Raghu Kalluri et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
HOXB13 promotes androgen independent growth of LNCaP prostate cancer cells by the activation of E2F signaling
Young-Rang Kim et al.
MOLECULAR CANCER (2010)
Telomerase as an Important Target of Androgen Signaling Blockade for Prostate Cancer Treatment
Shuang Liu et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases
Y. Liu et al.
ONCOGENE (2010)
Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells
N. Bhatnagar et al.
CELL DEATH & DISEASE (2010)
Steroid signaling activation and intracellular localization of sex steroid receptors
Tiziana Giraldi et al.
JOURNAL OF CELL COMMUNICATION AND SIGNALING (2010)
Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth
A. M. Traish et al.
BRITISH JOURNAL OF CANCER (2009)
Src Family Kinase Activity Is Up-Regulated in Hormone-Refractory Prostate Cancer
Oleg Tatarov et al.
CLINICAL CANCER RESEARCH (2009)
The natural compound atraric acid is an antagonist of the human androgen receptor inhibiting cellular invasiveness and prostate cancer cell growth
Maria Papaioannou et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2009)
Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: pivotal roles of Snail repression and RKIP induction
S. Baritaki et al.
ONCOGENE (2009)
Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth
R. Bruce Montgomery et al.
CANCER RESEARCH (2008)
Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530
Y-M Chang et al.
ONCOGENE (2008)
Expression of androgen receptor is negatively regulated by p53
Fatouma Alimirah et al.
NEOPLASIA (2007)
Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation
Nupam P. Mahajan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Androgen receptor coregulators and their involvement in the development and progression of prostate cancer
Renee Chmelar et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Inappropriate activation of the androgen receptor by nonsteroids: Involvement of the Src kinase pathway and its therapeutic implications
Sonal J. Desai et al.
CANCER RESEARCH (2006)
LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription
E Metzger et al.
NATURE (2005)
Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy
D Hirano et al.
EUROPEAN UROLOGY (2004)
Molecular determinants of resistance to antiandrogen therapy
CD Chen et al.
NATURE MEDICINE (2004)
Agonist-antagonist induced coactivator and corepressor interplay on the human androgen receptor
H Dotzlaw et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2003)
Drosophila enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal polycomb sites
B Czermin et al.
CELL (2002)
Share Paper
